Retatrutide

Retatrutide is an investigational once-weekly injectable peptide designed to treat obesity and type 2 diabetes by heavily targeting three metabolic receptors. It promotes significant weight loss, suppresses appetite, improves glycemic control, and enhances the body's natural fat-burning capabilities.

Three key metabolic receptors:

• GLP-1 (Glucagon-Like Peptide-1) → Enhances insulin secretion, suppresses appetite, delays gastric emptying
  
• GIP (Glucose-Dependent Insulinotropic Polypeptide) → Boosts insulin response, improves insulin sensitivity, may support lipid metabolism
  
• Glucagon Receptor (GCGR) → Elevates energy expenditure, promotes fat oxidation, and may reduce liver fat

This triple agonist profile delivers synergistic effects on glycemic control, fat loss, and metabolic health, making Retatrutide the most advanced incretin-based peptide in development.

Retatrutide sold on NextPhase Biolabs Website is strictly for research and laboratory use only. NOT FOR HUMAN OR ANIMAL USE.